digital therapeutics

By Jonah Comstock March 12, 2018
Digital therapeutics may be up and coming, but they also have a long way to go before their mainstream treatment options, according to experts who spoke at the digital therapeutics deep dive at HIMSS18. “This is going to be a completely new industry sector,” Pierre Leurent, CEO of Voluntis, said during the session. “It’s going to have very strong growth in the years to come and it’s going to be a...
By Dave Muoio March 2, 2018
 From syringes to workflow management systems, healthcare is no stranger to adopting new technologies into standard care. As digital and connected technologies continue to stake their claim in the industry, the last few years have seen the rise of a new type of health technology product — one that promises measurable health outcomes validated by traditional clinical trials.   “You had a little...
By Jonah Comstock March 1, 2018
Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia. It’s the first time a pharma company has made a development deal with a digital therapeutic, according to Pear. “We have been in discussions for many months now with the [Novartis Institutes for BioMedical Research] group at...
By Jonah Comstock February 15, 2018
San Francisco-based FareWell is changing its name to Better Therapeutics, a rebranding that reflects the company’s shift in focus from weight loss and disease prevention to digital therapeutics to treat chronic diseases. To punctuate that shift, Better Therapeutics is announcing the name change on the same day as the publication of a study in the Journal of Medical Internet Research that...
By Jonah Comstock January 26, 2018
Last week, we published part 1 of our digital health trends and predictions piece, covering big picture trends like vertical integration and healthcare consumerization, as well as some of the buzzy tech trends of voice, AI, and blockchain. This week, with the help of a range of expert stakeholders, we’re zooming in on four specific areas in digital health to look at what we can expect in the year...
By Dave Muoio January 4, 2018
An analysis contracted by WellDoc found that the company’s digital therapeutic for Type 2 diabetes management could lead to an average savings of more than $250 per patient per month. “The cost of a well-controlled diabetes patient will typically range in the $13,000 range [to] $20,000 annually. When you contrast that with the cost of a patient that doesn’t have diabetes, that number is typically...
By Dave Muoio January 2, 2018
Boston- and San Francisco-based Pear Therapeutics, maker of a prescription digital therapeutic platform, announced today the closure of $50 million in Series B funding. The round was led by Singapore-based investment company Temasek, with participation from returning investors 5AM Ventures, Arboretum Ventures, and JAZZ Venture Partners, as well as new partners Novartis, EDBI, and the Bridge...
By Dave Muoio December 4, 2017
Boston-based Akili Interactive Labs has announced positive results from the largest clinical trial of its video game-based pediatric ADHD treatment yet. In light of these data, the company announced that it now plans to file AKL-T01, also known as Project: Evo ADHD Treatment, for FDA clearance as a novel treatment for children and adolescents with ADHD “This is, any way you slice it, our largest...
By Jonah Comstock October 25, 2017
A group of  health startups in the burgeoning digital therapeutics space have joined together to create a new industry association, the Digital Therapeutics Alliance (DTA). “Digital therapeutics are re-writing our definition of medicine,” Akili Interactive CEO Eddie Martucci said in a statement. “It’s critical that industry, academia, government, and the medical community work together in the...
By Jonah Comstock September 14, 2017
In an FDA first, Boston- and San Francisco-based Pear Therapeutics' reSET system for the treatment of substance abuse has been granted a de novo clearance by the agency. It's the first software-only digital therapeutic the FDA has cleared with claims to improve clinical outcomes in a disease. “This is a defining moment for digital therapeutics and for patients with substance use disorder,” Corey...

Editor's Pick